Polypill and colchicine for heart and artery risk
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a combination pill (polypill) and a medicine called colchicine to see if they can lower the risk of future heart attacks, strokes, or other artery problems. It is for people who already have a history of heart or blood vessel disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years old or older.
- You have had a heart attack, stroke, or a procedure to open a blocked artery, or you have a major artery blockage (50% or more).
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have advanced kidney or liver disease, or a muscle disease.
- You are not taking blood thinners (except for a low dose of rivaroxaban for peripheral artery disease) or colchicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a low dose of colchicine, a medicine that reduces inflammation, can help improve blood vessel and bone health in people with moderate chronic kidney disease.
This trial tests whether taking colchicine can prevent coronary artery disease (heart artery blockages) in people who have several heart risk factors but do not already have diagnosed disease. It aims to see if colchicine lowers the chance of developing heart artery problems over time.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This trial tests if colchicine, a common anti-inflammatory medicine, can help prevent future heart problems in people who have coronary artery disease and recently had a stent placed. It's for adults with at least one extra risk factor like diabetes, smoking, or high blood pressure.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
This trial tests whether adding a targeted anti-inflammatory drug to standard care can prevent future heart attacks or strokes in people with high-risk chronic coronary artery disease. It is for people who have a moderate narrowing in a heart artery with a vulnerable plaque and signs of inflammation.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.